A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

Primary Myelofibrosis Clinical Trial

Official title:

A Phase II, Prospective, Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Asian Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post- Essential Thrombocythemia Myelofibrosis

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02584777
• Other study ID #: 381401
• Status: Withdrawn
• Phase: Phase 2
• Start date: November 30, 2015
• Est. completion date: August 31, 2020

Study information

• Verified date: May 2021
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of pacritinib in Asian subjects with myelofibrosis (MF), which includes primary MF (PMF), post-polycythemia vera MF (PPV-MF) or post-essential thrombocythemia MF (PET-MF).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 31, 2020
• Est. primary completion date: September 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Intermediate-1, intermediate-2, or high-risk PMF, PPV-MF or PET-MF as based on The Dynamic International Prognostic Scoring System (DIPSS) criteria

2. Palpable splenomegaly =5 cm below the LCM in midclavicular line by physical examination

3. TSS =13 on the MPN-SAF TSS 2.0, not including the inactivity question, based on a single assessment during screening visit

4. Age =18 years old at the time of screening (or minimum age of legal consent consistent with local regulations, if minimum is >18 years of age)

5. ECOG performance status 0 to 3

6. Peripheral blast count <10%

7. Absolute neutrophil count >500/µL

8. Participants who are platelet or RBC transfusion dependent are eligible

9. Adequate liver and renal function, defined by liver transaminases (AST/serum glutamic oxaloacetic transaminase [SOOT] and alanine aminotransferase [ALT]/serum glutamic pyruvic transaminase [SGPT]) =3 × upper limit of normal ([ULN], AST/ALT =5 × ULN if transaminase elevation is related to MF), direct bilirubin =4 × ULN, and creatinine =2.5 mg/dL

10. At least 6 months from prior splenic irradiation

11. At least 12 months from prior 32P therapy

12. At least 1 week since prior treatment (most recent dose) with a potent CYP3A4 inhibitor or inducer

13. At least 4 weeks since any experimental treatment for PMF, PPV-MF, or PET-MF

14. At least 2 weeks since any treatment for PMF, PPV-MF, or PET-MF

15. If fertile, both males and females must agree to use effective birth control.

16. Able to understand and willing to complete symptom assessments using a patient-reported outcomes instrument and comply with treatment and study procedures of the protocol

17. Able to understand and willing to sign the informed consent form (ICF)

18. Participant is willing and able to comply with the requirements of the protocol

Exclusion Criteria:

1. Any GI or metabolic condition that could interfere with absorption of oral medication

2. Life expectancy <6 months

3. Prior treatment with a JAK2 inhibitor

4. Completed ASCT, or are eligible for and willing to complete ASCT

5. History of splenectomy or planning to undergo splenectomy

6. Uncontrolled intercurrent illness, including but not limited to ongoing active infection, or psychiatric illness, or social situation that, in the judgment of the treating physician, would limit compliance with study requirements

7. Other malignancy within the last 3 years, other than curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, organ confined, or treated non-metastatic prostate cancer with negative prostate specific antigen, in situ breast carcinoma after complete surgical resection, or superficial transitional cell bladder carcinoma

8. Inflammatory or chronic functional bowel disorder, such as Crohn's disease, inflammatory bowel disease, chronic diarrhea, or constipation

9. Clinically symptomatic and uncontrolled cardiovascular disease

10. History of any of the following within 6 months prior to first dose of pacritinib:

myocardial infarction, severe/unstable angina, or symptomatic congestive heart failure

11. New York Heart Association Class II, III, or IV congestive heart failure

12. Participants with NCI CTCAE (version 4.03) Grade 2 cardiac arrhythmias may be considered for inclusion, with the approval of the medical monitor, if the arrhythmias are stable, asymptomatic and unlikely to affect participant safety. Participants will be excluded if they have ongoing cardiac dysrhythmias of NCI CTCAE Grade =3, QTc prolongation >450 ms, or other conditions that increase the risk for QT interval prolongation (eg, heart failure, hypokalemia [defined as serum potassium <3.0 mEq/L that is persistent and refractory to correction], or family history of long QT interval syndrome)

13. Erythropoietic agent within 28 days prior to first dose of pacritinib

14. Thrombopoietic agent within 14 days prior to first dose of pacritinib

15. Known seropositivity for human immunodeficiency virus or syphilis, or known active hepatitis A, B or C virus infection

16. Participant has participated in another clinical study involving an IP or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study

17. Participant is a family member or employee of the investigator

18. If female, participant is pregnant or breastfeeding at the time of enrollment. Even if breastfeeding can be discontinued, the participant should not be enrolled in the study

Related Conditions & MeSH terms

• Polycythemia Vera
• Primary Myelofibrosis

Intervention

Biological:
• Pacritinib
QD (Once a day)

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Baxalta now part of Shire	CTI BioPharma

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants achieving a =35% reduction in spleen volume	Measured by MRI or CT scan	Baseline to Week 24
Secondary	Proportion of participants with =50% reduction in total symptom score (TSS)	Measured by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) TSS 2.0	Baseline to Week 24
Secondary	Proportion of participants with baseline platelet count <100,000/µL achieving =35% reduction in spleen volume	Measured by MRI or CT scan	Baseline to Week 24
Secondary	Proportion of participants with baseline platelet count <100,000/µL achieving =50% reduction in total symptom score (TSS)		Baseline to Week 24
Secondary	Proportion of participants with baseline platelet count <50,000/µL achieving =35% reduction in spleen volume	Measured by MRI or CT scan	Baseline to Week 24
Secondary	Proportion of participants with baseline platelet count <50,000/µL achieving =50% reduction in total symptom score (TSS)		Baseline to Week 24
Secondary	Clinically significant adverse events (AEs)		Throughout the study period of approximately 5 years
Secondary	Clinically significant changes in laboratory results		Throughout the study period of approximately 5 years
Secondary	Clinically significant changes in vital signs		Throughout the study period of approximately 5 years
Secondary	Clinically significant changes in electrocardiograms (ECGs)		Throughout the study period of approximately 5 years
Secondary	Pacritinib pharmacokinetic (PK) parameter: maximum observed concentration (Cmax)		Baseline; weeks 3, 12 & 24
Secondary	Pacritinib pharmacokinetic (PK) parameter: Time of maximum observed concentration (Tmax)		Baseline; weeks 3, 12 & 24
Secondary	Pacritinib pharmacokinetic (PK) parameter: minimum observed concentration (Cmin)		Baseline; weeks 3, 12 & 24
Secondary	Pacritinib pharmacokinetic (PK) parameter: area under the concentration curve (AUC)		Baseline; weeks 3, 12 & 24
Secondary	Pacritinib pharmacokinetic (PK) parameter: apparent volume of distribution (V/F)		Baseline; weeks 3, 12 & 24
Secondary	Pharmacodynamic parameter: Maximum observed effect (Emax)		Baseline; weeks 3, 12 & 24
Secondary	Pharmacodynamic parameter: time of maximum observed effect (tEmax)		Baseline; weeks 3, 12 & 24
Secondary	Pharmacodynamic parameter: area under the effect curve (AUEC)		Baseline; weeks 3, 12 & 24